top biopharmaceuticals for glp-1 medication Eli Lilly Overtakes Novo Nordisk in GLP-1s by 2026 | Bryce Platt, PharmD posted on the topic Top 12 Pharma: Pfizer Tops

In addition to focusing on new indications, Merck is also betting on Keytruda's combination therapies

Recent developments: April 2026, The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, potentially limiting large-scale compounding activities

They keep pushing forward with research thats tied to metabolic disorders and more advanced care options

Your medical provider will determine if theyre right for your health profile

[3] A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)

The study was sponsored by Eli Lilly and Company, the manufacturer of orforglipron and the injectable GLP-1 tirzepatide